Anti-Fungal Treatment Study Updated by NexMed (NEXM)

October 14, 2009 9:38 AM EDT

NexMed, Inc. (Nasdaq: NEXM) today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis (nail fungus). NexMed seeks to pursue signing a partner for further development of the product.

NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.


Related Categories

Corporate News

Stocks Mentioned

NEXM 0.49

+0.00 +0.00%
Volume: 1,766,887
Track NEXM


Add Your Comment





Follow StreetInsider.com On Twitter